Clinical Trials in Tennessee

Showing 10621-10640 of 15,329 trials

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

NCT01616199

The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose (MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. The purpose of the phase 2 portion of the study is to compare progression free survival (PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and tolerability of PX-866 in combination with vemurafenib vs. vemurafenib alone in patients with advanced BRAF-mutant melanoma at the doses recommended from Phase 1.

Advanced BRAF-mutant Cancers

Cascadian Therapeutics Inc.24 participantsStarted Aug 2012

Tampa, Florida, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States +2 more locations

TERMINATEDPhase 329 miles

A Study in Participants With Rheumatoid Arthritis

NCT01202773

The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α) inhibitors. This study is comprised of 2 periods: Period 1: 24-week blinded treatment Period 2: 48-week post-treatment follow-up

Rheumatoid Arthritis

Eli Lilly and Company456 participantsStarted Jan 2011

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Paradise Valley, Arizona, United States +198 more locations

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

A Study in Participants With Rheumatoid Arthritis

Find Trials by Condition in Tennessee

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Phase 1 and 2 Study of PX-866 and Cetuximab

Radiosurgery or Open Surgery for Epilepsy Trial

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

PF-00489791 For The Treatment Of Raynaud's

Behavioral & Nutritional Treatment to Help CF Preschoolers Grow

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Neurostimulation for the Relief of Acute Bronchoconstriction

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair

Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

The Impact of Vitamin D on Disease Activity in Crohn's Disease